PNC Financial Services Group Inc. maintained its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) during the second quarter, Holdings Channel reports. The fund owned 13,807 shares of the company’s stock at the end of the second quarter. PNC Financial Services Group Inc. owned 0.11% of Oramed Pharmaceuticals worth $115,000 at the end of the most recent quarter.

Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) traded down 0.5644% during midday trading on Tuesday, reaching $7.3284. The company’s stock had a trading volume of 6,718 shares. The company’s market capitalization is $96.27 million. Oramed Pharmaceuticals Inc. has a 12-month low of $5.60 and a 12-month high of $10.74. The company’s 50-day moving average price is $7.45 and its 200 day moving average price is $8.06.

Separately, Rodman & Renshaw reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Oramed Pharmaceuticals in a research note on Sunday, August 21st. Five investment analysts have rated the stock with a buy rating, Oramed Pharmaceuticals has a consensus rating of “Buy” and an average price target of $22.00.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

5 Day Chart for NASDAQ:ORMP

Want to see what other hedge funds are holding ORMP? Visit to get the latest 13F filings and insider trades for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP).

Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.